TMC Life Sciences Berhad Balance Sheet Health
Financial Health criteria checks 6/6
TMC Life Sciences Berhad has a total shareholder equity of MYR891.0M and total debt of MYR197.7M, which brings its debt-to-equity ratio to 22.2%. Its total assets and total liabilities are MYR1.2B and MYR287.1M respectively. TMC Life Sciences Berhad's EBIT is MYR41.4M making its interest coverage ratio 9.1. It has cash and short-term investments of MYR172.4M.
Key information
22.2%
Debt to equity ratio
RM 197.69m
Debt
| Interest coverage ratio | 9.1x |
| Cash | RM 172.41m |
| Equity | RM 890.98m |
| Total liabilities | RM 287.09m |
| Total assets | RM 1.18b |
Recent financial health updates
TMC Life Sciences Berhad (KLSE:TMCLIFE) Seems To Use Debt Quite Sensibly
Feb 14
We Think TMC Life Sciences Berhad (KLSE:TMCLIFE) Can Stay On Top Of Its Debt
Sep 29Recent updates
TMC Life Sciences Berhad (KLSE:TMCLIFE) Seems To Use Debt Quite Sensibly
Feb 14We Think TMC Life Sciences Berhad (KLSE:TMCLIFE) Can Stay On Top Of Its Debt
Sep 29Investors Met With Slowing Returns on Capital At TMC Life Sciences Berhad (KLSE:TMCLIFE)
Aug 26TMC Life Sciences Berhad (KLSE:TMCLIFE) Shareholders Will Want The ROCE Trajectory To Continue
May 26TMC Life Sciences Berhad's (KLSE:TMCLIFE) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Feb 09Returns On Capital - An Important Metric For TMC Life Sciences Berhad (KLSE:TMCLIFE)
Jan 13Financial Position Analysis
Short Term Liabilities: TMCLIFE's short term assets (MYR250.7M) exceed its short term liabilities (MYR90.3M).
Long Term Liabilities: TMCLIFE's short term assets (MYR250.7M) exceed its long term liabilities (MYR196.7M).
Debt to Equity History and Analysis
Debt Level: TMCLIFE's net debt to equity ratio (2.8%) is considered satisfactory.
Reducing Debt: TMCLIFE had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: TMCLIFE's debt is well covered by operating cash flow (26.5%).
Interest Coverage: TMCLIFE's interest payments on its debt are well covered by EBIT (9.1x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:54 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
TMC Life Sciences Berhad is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shin Kao | OSK-DMG |